Screener
Arbutus Biopharma Corporation ABUS Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Collaborations and licenses | $202K-98.0% | $204K-84.5% | $792K-25.1% | $280K-63.5% | $10.21M+784% | |
| Non-cash royalty revenue | $180K-65.8% | $181K-59.6% | $259K-49.8% | $249K-56.5% | $526K-7.9% | |
| Revenue from collaborations and licenses | $632K-93.4% | $178.74M+21,912% | $0-100% | $280K-56.5% | $9.62M+1,399% |
FAQ
- How does Arbutus Biopharma Corporation break its business down?
- Arbutus Biopharma Corporation (ABUS) reports revenue by product across 3 parts — Collaborations and licenses, Non-cash royalty revenue and Revenue from collaborations and licenses. Each is extracted from the segment footnotes and tracked over time.
- Where does Arbutus Biopharma Corporation's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Arbutus Biopharma Corporation's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
